drugset / Trial / NCT00324922

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

NCT00324922

Phase 3 Completed 2 enrolled University of Washington
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary question of this study is to understand if trimethoprim-sulfamethoxazole (TMP-SMX) is as effective as vancomycin for treating methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.

Timeline

Start
2006-05-01
Primary completion
2007-05-01
Completion
2007-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sulfamethoxazole Small molecule 1600 mg Oral
Comparator Trimethoprim Small molecule 320 mg Oral
Comparator Vancomycin Other / unclassified 1 g Intravenous